CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
-3.55%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$2.69B
AUM Growth
+$2.69B
(+5.7%)
Cap. Flow
+$240M
Cap. Flow
% of AUM
8.9%
Top 10 Holdings %
Top 10 Hldgs %
53.13%
Holding
41
New
8
Increased
11
Reduced
8
Closed
4
Top Buys
| 1 |
Zimmer Biomet
ZBH
|
$106M |
| 2 |
Universal Health Services
UHS
|
$93.4M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$88.9M |
| 4 |
Sarepta Therapeutics
SRPT
|
$46.2M |
| 5 |
Sanofi
SNY
|
$36.2M |
Top Sells
| 1 |
Cardinal Health
CAH
|
$71.4M |
| 2 |
The Beauty Health Co
SKIN
|
$67.2M |
| 3 |
Alkermes
ALKS
|
$48.6M |
| 4 |
Hologic
HOLX
|
$44.4M |
| 5 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
$38.6M |
Sector Composition
| 1 | Healthcare | 96.2% |
| 2 | Technology | 3.11% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Universal Health Services
UHS
$11.6B
| $201M | 6.18% | 1,450,000 +675,000 | +87% | +$93.4M |
|
|
WBA
2
DELISTED
Walgreens Boots Alliance
WBA
| $188M | 5.8% | 4,000,000 +500,000 | +14% | +$23.5M |
|
3
Tenet Healthcare
THC
$16.3B
| $183M | 5.63% | 2,750,000 -100,000 | -4% | -$6.64M |
|
4
Viatris
VTRS
$12.3B
| $163M | 5.01% | 12,000,000 | – | – |
|
|
5
Sanofi
SNY
$121B
| $145M | 4.45% | 3,000,000 +750,000 | +33% | +$36.2M |
|
6
Perrigo
PRGO
$3.27B
| $118M | 3.64% | 2,500,000 | – | – |
|
7
Merck
MRK
$210B
| $113M | 3.47% | 1,500,000 | – | – |
|
8
HCA Healthcare
HCA
$94.5B
| $109M | 3.34% | 447,500 -152,500 | -25% | -$37M |
|
|
9
Zimmer Biomet
ZBH
$21B
| $106M | 3.27% | +725,090 | New | +$106M |
|
10
GSK
GSK
$79.9B
| $105M | 3.24% | 2,750,000 | – | – |
|
11
Brookdale Senior Living
BKD
$1.83B
| $101M | 3.1% | 16,000,000 +650,000 | +4% | +$4.1M |
|
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $88.9M | 2.74% | +1,150,000 | New | +$88.9M |
|
13
Myriad Genetics
MYGN
$593M
| $88.8M | 2.73% | 2,750,000 -250,000 | -8% | -$8.07M |
|
|
14
Alkermes
ALKS
$4.78B
| $84M | 2.59% | 2,725,000 -1,575,000 | -37% | -$48.6M |
|
15
Ionis Pharmaceuticals
IONS
$6.79B
| $83.9M | 2.58% | 2,500,000 +500,000 | +25% | +$16.8M |
|
|
CHNG
16
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $83.8M | 2.58% | 4,000,000 +1,650,000 | +70% | +$34.6M |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $79.6M | 2.45% | 450,000 +50,000 | +13% | +$8.85M |
|
18
Gilead Sciences
GILD
$140B
| $76.8M | 2.37% | 1,100,000 -300,000 | -21% | -$21M |
|
19
Ironwood Pharmaceuticals
IRWD
$214M
| $71.8M | 2.21% | 5,500,000 -2,000,000 | -27% | -$26.1M |
|
|
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $68.9M | 2.12% | 685,000 +220,000 | +47% | +$22.1M |
|
21
Nektar Therapeutics
NKTR
$568M
| $67.4M | 2.07% | 3,750,000 +250,000 | +7% | +$4.49M |
|
22
Teva Pharmaceuticals
TEVA
$21.1B
| $48.7M | 1.5% | 5,000,000 -500,000 | -9% | -$4.87M |
|
23
OraSure Technologies
OSUR
$242M
| $48.1M | 1.48% | 4,250,000 +675,000 | +19% | +$7.63M |
|
|
24
Sarepta Therapeutics
SRPT
$1.78B
| $46.2M | 1.42% | +500,000 | New | +$46.2M |
|
25
Collegium Pharmaceutical
COLL
$1.22B
| $39.5M | 1.22% | 2,000,000 | – | – |
|